Latest | F'cast | |
---|---|---|
Div Yield | 1.0% | 0.0% |
Div Cover | 4.9 | n/a |
Op Mrgn | 5.1% | n/a |
ROCE | 10.3% |
Latest | F'cast | |
---|---|---|
P/E | 20.7 | n/a |
PEG | 0.7 | n/a |
Pr/Revenue | 1.1 | n/a |
Pr/Book | 1.4 |
Latest | F'cast | |
---|---|---|
Revenue | 14.5% | n/a |
PBT | 18.8% | n/a |
EPS | 28.2% | n/a |
DPS | 4.3% | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-May-21 | 98.52 | 5.45 | 22.80p | 14.7 | 0.1 | +182% | 4.00p | 1.2% |
31-May-22 | 99.07 | 6.97 | 21.60p | 20.8 | n/a | -5% | 4.20p | 0.9% |
31-May-23 | 116.44 | 7.48 | 23.40p | 17.5 | 2.2 | +8% | 4.50p | 1.1% |
31-May-24 | 136.62 | 4.82 | 18.80p | 20.5 | n/a | -20% | 4.70p | 1.2% |
31-May-25 | 156.41 | 6.86 | 24.10p | 17.0 | 0.6 | +28% | 4.90p | 1.2% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Exercise of Options & Total Voting Rights | 01-Oct-2025 | 16:52 | RNS |
Holding(s) in Company | 01-Oct-2025 | 15:32 | RNS |
Appointment of Medical Division CEO | 29-Sep-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 500.00p |
Change Today | 7.00p |
% Change | 1.42 % |
52 Week High | 510.00 |
52 Week Low | 310.00 |
Volume | 73,972 |
Shares Issued | 33.09m |
Market Cap | £165.45m |
Beta | 0.01 |
RiskGrade | 130 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Latest | Previous | |
---|---|---|
Final | Interim | |
Ex-Div | 06-Nov-25 | 29-May-25 |
Paid | 19-Dec-25 | 27-Jun-25 |
Amount | 3.00p | 1.90p |
Time | Volume / Share Price |
16:22 | 5,000 @ 505.00p |
14:03 | 25,000 @ 500.00p |
16:14 | 264 @ 500.00p |
16:07 | 2,950 @ 498.00p |
16:02 | 48 @ 508.90p |
Finance Director | Stephen King |
Chair | Roger Steven McDowell |
CEO | Stephen McQuillan |
You are here: research